Personal Profile
Dr. Trivedi graduated from St. George’s Hospital Medical School (London, UK) in 2005, going on to complete foundation medical training in the Kent, Surrey and Sussex deanery in 2007. He undertook specialty training in internal medicine within the Oxford Deanery and was appointed as a specialist registrar in gastroenterology in 2009. In 2011, Dr. Trivedi began doctoral research training at the National Institute for Health Research in Birmingham, writing a thesis on how gut inflammation may influence the development and progression of autoimmune liver disease. His works in primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) received awards for the best research in liver medicine (2014) and liver transplantation (2017 and 2018).
Dr. Trivedi was appointed to a faculty position in 2018. He is an Associate Professor at the National Institute for Health Research (NIHR) Birmingham Biomedical Research Centre (BRC), Chief Investigator for the UK-Primary Sclerosing Cholangitis (PSC) consortium, elected chair of the British Association for Study of the Liver Special Interest Group (BASL SIG) for immune-mediated liver disease, and elected steering committee member of the Global Primary Biliary Cholangitis (PBC) Study Group and the International PSC Study Group. He is chief or principal investigator for over 25 clinical trials, including lead for four academic multicentre studies looking at how the gut microbiome can be targeted for the benefit of liver disease. He has >90 articles on PubMed, >50 in the last five years alone; with 40 as original articles, and 45 as first or lead author. The overarching themes of research are in the role of gut-liver immunity, modelling the natural history of rare liver disease, diagnostics of rare liver disease, and symptom-directed therapy. He currently supervises a diverse programme, with several PhD students, postdoctoral researcher and research project managers.
Dr. Trivedi is an accredited gastrointestinal endoscopist, with skills in variceal surveillance and banding, and in the investigation and treatment of gastrointestinal bleeding. He holds active roles in medical education for the Birmingham medical degree programme. He is the lead for gastroenterology and hepatology module (years 4 and 5), and regularly examines PhD students nationally and internationally.
Dr. Trivedi was appointed to a faculty position in 2018. He is an Associate Professor at the National Institute for Health Research (NIHR) Birmingham Biomedical Research Centre (BRC), Chief Investigator for the UK-Primary Sclerosing Cholangitis (PSC) consortium, elected chair of the British Association for Study of the Liver Special Interest Group (BASL SIG) for immune-mediated liver disease, and elected steering committee member of the Global Primary Biliary Cholangitis (PBC) Study Group and the International PSC Study Group. He is chief or principal investigator for over 25 clinical trials, including lead for four academic multicentre studies looking at how the gut microbiome can be targeted for the benefit of liver disease. He has >90 articles on PubMed, >50 in the last five years alone; with 40 as original articles, and 45 as first or lead author. The overarching themes of research are in the role of gut-liver immunity, modelling the natural history of rare liver disease, diagnostics of rare liver disease, and symptom-directed therapy. He currently supervises a diverse programme, with several PhD students, postdoctoral researcher and research project managers.
Dr. Trivedi is an accredited gastrointestinal endoscopist, with skills in variceal surveillance and banding, and in the investigation and treatment of gastrointestinal bleeding. He holds active roles in medical education for the Birmingham medical degree programme. He is the lead for gastroenterology and hepatology module (years 4 and 5), and regularly examines PhD students nationally and internationally.
